Indivior (INDV) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
15 Oct, 2026Opening remarks and agenda
Meeting called to order at 10:00 a.m. ET on October 15, 2026; agenda set out in the proxy statement first made available on or about September 11, 2026.
September 4, 2026 was the record date; holders of a majority in voting power of outstanding shares were present or represented, establishing a quorum.
Polls opened at 10:02 a.m. ET; online voting remained available until polls closed, and proxies already submitted counted automatically.
Specific resolutions to be voted on
Share issuance proposal: approve issuing common stock in connection with the merger under the merger agreement, including for compliance with NASDAQ Rule 5635.
Adjournment proposal: approve one or more adjournments if needed, including to solicit additional votes or proxies for the share issuance proposal.
Discussions on mergers, acquisitions, or other significant changes
Proposed common-stock issuance was linked to the merger contemplated by the merger agreement.
Latest events from Indivior
- Record SUBLOCADE sales lifted Q3 results ahead of the Supernus merger and $1B dividend.INDV
Q3 2026 - Merger forms a $2.2B CNS biopharma leader with strong growth, profitability, and synergies.INDV
Corporate presentation - Q2 2026 saw record results and a merger to form a CNS leader with $2.2B revenue and $888M EBITDA.INDV
Q2 2026 & Merger - SUBLOCADE's growth accelerates with DTC and commercial gains as diversification plans advance.INDV
Jefferies Global Healthcare Conference 2026 - All proposals, including director elections and auditor ratification, were approved.INDV
AGM 2026 - Q1 2026 delivered record EBITDA, 19% revenue growth, and raised guidance on SUBLOCADE strength.INDV
Q1 2026 - Strong financial results, U.S. redomicile, and robust governance mark a pivotal year.INDV
Proxy filing - SUBLOCADE growth, cost cuts, and organizational overhaul drive the 2025–2026 strategy.INDV
Morgan Stanley 23rd Annual Global Healthcare Conference - SUBLOCADE growth drove FY 2024 gains, but 2025 faces a 17% revenue decline from SUBOXONE Film erosion.INDV
Q4 2024